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Abstract
Introduction Ataxia-telangiectasia is an autosomal-recessive
disease that affects neuro-immunological functions, associated
with increased susceptibility to malignancy, chromosomal
instability and hypersensitivity to ionizing radiation. Although
ataxia-telangiectasia mutated (ATM) heterozygous deficiency
has been proposed to increase susceptibility to breast cancer,
some studies have not found excess risk. In experimental
animals, increased susceptibility to breast cancer is not
observed in the Atm  heterozygous deficient mice (Atm+/-)
carrying a knockout null allele. In order to determine the effect of
Atm heterozygous deficiency on mammary tumourigenesis, we
generated a series of Atm+/- mice on the p53+/- background with
a certain predisposition to spontaneous development of
mammary carcinomas, and we examined the development of the
tumours after X-irradiation.
Methods BALB/cHeA-p53+/- mice were crossed with MSM/
Ms-Atm+/- mice, and females of the F1 progeny ([BALB/cHeA ×
MSM/Ms]F1) with four genotypes were used in the experiments.
The mice were exposed to X-rays (5 Gy; 0.5 Gy/min) at age 5
weeks.
Results We tested the effect of haploinsufficiency of the Atm
gene on mammary tumourigenesis after X-irradiation in the
p53+/- mice of the BALB/cHeA × MSM/Ms background. The
singly heterozygous p53+/-  mice subjected to X-irradiation
developed mammary carcinomas at around 25 weeks of age,
and the final incidence of mammary carcinomas at 39 weeks
was 31% (19 out of 61). The introduction of the heterozygous
Atm knockout alleles into the background of the p53+/- genotype
significantly increased the incidence of mammary carcinoma to
58% (32 out of 55) and increased the average number of
mammary carcinomas per mouse. However, introduction of Atm
alleles did not change the latency of development of mammary
carcinoma.
Conclusion Our results indicate a strong enhancement in
mammary carcinogenesis by Atm  heterozygous deficiency in
p53+/- mice. Thus, doubly heterozygous mice represent a useful
model system with which to analyze the interaction of
heterozygous genotypes for p53, Atm  and other genes, and
their effects on mammary carcinogenesis.
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Introduction
Ataxia-telangiectasia is an autosomal-recessive disease
that affects neuro-immunologic functions, and is associ-
ated with increased susceptibility to malignancy, chromo-
somal instability and hypersensitivity to ionizing radiation
[1,2].  ATM  (ataxia-telangiectasia mutated) heterozygous
deficiency has been proposed to increase susceptibility to
breast cancer [3-7]. However, those early studies were lim-
ited by the lack of reliable assays with which to identify car-
riers [8]. In fact, in a later study a lack of association of
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heterozygous  ATM  mutations with early onset of breast
cancer was found [9]. More recent epidemiological studies
suggested that missense mutation in the ATM gene, rather
than a protein-truncating mutation, which accounts for the
majority of mutations in patients with ataxia-telangiectasia,
confers increased risk for breast cancer [10]. Thus, cancer
risk in ATM heterozygotes varies depending on the muta-
tion type (i.e. some missense-type mutations are associ-
ated with early onset of breast carcinoma whereas
truncation-type mutations are not) [11,12]. Recently, epide-
miological studies on excess risk for breast cancer in ATM
heterozygosity were reported [13].
In experimental animals, no tumours were observed in Atm
heterozygous mice carrying a knockout null allele of Atm
[14]. In contrast, Atm knock-in heterozygous mice harbour-
ing an in-frame deletion corresponding to the human muta-
tion exhibit increased susceptibility to a wide variety of
tumours [14]. Thus, data in humans and mice suggest that
the type of Atm mutation determines susceptibility to can-
cer in heterozygous individuals. Heterozygosity for a null
knockout allele of Atm in mice and protein-truncating alleles
of ATM in humans was thought not to increase susceptibil-
ity to mammary cancer. On the other hand, haploinsuffi-
ciency at the Atm  gene has a phenotype of increased
sensitivity to ionizing radiation in mice [15].
In contrast to the Atm gene, the p53 null allele exhibits hap-
loinsufficiency for the development of tumours in mice,
mainly lympho-haematopoietic malignancies [16,17]. The
p53 heterozygotes of BALB/c genetic background develop
mammary tumours [18-20]. Mice doubly null for the p53
and Atm genes were reported to exhibit a dramatic accel-
eration in tumour formation relative to singly null mice, indi-
cating that the genes cooperate in a significant manner to
prevent tumourigenesis [21]. However, the authors noted
no mammary carcinoma in any of the four genotypes stud-
ied (p53+/+ Atm-/-, p53+/- Atm-/-, p53-/- Atm+/-, and p53-/-
Atm-/-). Thus, the significance of haploinsufficiency of the
Atm null allele in mammary carcinogenesis is obscure at
present.
In order to determine the effect of Atm heterozygous defi-
ciency on mammary tumourigenesis, we generated a series
of Atm+/- mice on the background of p53+/- mice with a cer-
tain predisposition to spontaneous development of mam-
mary carcinomas, and we examined the development of
tumours after X-irradiation. Our results indicate a strong
enhancement of mammary carcinogenesis in the Atm het-




The p53 targeted allele generated by Donehower and cow-
orkers [22] was introduced into the BALB/cHeA mouse at
The Netherlands Cancer Institute (Amsterdam). The p53
heterozygous deficient mice (p53+/-) were repeatedly back-
crossed to BALB/cHeA mice more than 30 times, and
maintained at the animal facility of Osaka Prefecture Univer-
sity. The Atm  targeted mouse (129/SvEv-Atmtm1Awb/+
mouse) was originally generated in the Jackson Laboratory
[23]. The Atm heterozygous deficient mice (Atm+/-) were
repeatedly backcrossed more than 10 times to MSM/Ms
mice. The BALB/cHeA-p53+/-  mice were crossed with
MSM/Ms-Atm+/-  mice, and females of the F1  progeny
([BALB/cHeA × MSM/Ms]F1) with four genotypes (i.e.
p53+/-  Atm+/-,  p53+/-  Atm+/+,  p53+/+  Atm+/-  and  p53+/+
Atm+/+) were used in the experiments. The conditions for
breeding were described previously [24].
X-irradiation
Mice were exposed at 5 weeks of age to X-rays (5 Gy; 260
kV, 12.0 mA, 0.3 mm Cu + 0.5 mm Al filter; 0.5 Gy/min)
from an X-ray generator (Radioflex 350; Rigaku Industrial
Co., Takatsuki, Japan). All animal experiments were carried
out in accordance with the standards relating to the care
and management of experimental animals (Japan) and
Osaka Prefecture University's guidelines for animal care
and use.
Histopathological examination
Moribund mice were killed by cervical dislocation for
autopsy. In cases of thymic lymphoma, the enlarged thy-
muses were examined as previously described [25]. In
tumour-bearing mice the tumours were fixed in 10% buff-
ered formalin, processed histologically, and stained with
haematoxylin and eosin. The processed tumour specimens
were evaluated by medical and veterinary pathologists
using the Annapolis guidelines established by Cardiff and
coworkers [26].
DNA isolation and genotyping
Normal and mammary carcinoma tissues were removed.
Isolation of DNA, PCR amplification, electrophoresis of
PCR products and assessment of allelic losses were per-
formed according to a procedure described previously
[24]. Genotypes for the wild-type and targeted alleles of
p53 and Atm genes were determined by analyzing the PCR
products for these alleles. Amplification for the p53 alleles
was done as described elsewhere [27]. The wild-type and
the targeted alleles of the p53 gene were amplified by PCR
using primers p53-4F (5'-CGACCTCCGTTCTCTCTC-
CTCTCTT-3') and p53-6R (5'-AGACGCACAAAC-
CAAAACAAAATTACA-3'), and primers p53-NF (5'-
GCCTTCTATCGCCTTCTTGACGAGT-3') and p53-6R,
respectively. Similarly, amplification of the wild-type and theAvailable online http://breast-cancer-research.com/content/7/1/R164
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targeted allele of the Atm gene were performed by using
primers IMR0640F (5'-GCTGCCATACTTGATCCATG-3')
and IMR0641R (5'-TCCGAATTTGCAGGAGTTG-3'), and
primers IMR0640F and AtmNeo410R (5'-CGGTGGAT-
GTGGAATGTGTG-3'), respectively.
Statistical analysis
Statistical significance was evaluated for the incidence of
mammary carcinoma and number of carcinomas per mouse
by  χ2  analysis and Mann–Whitney U-test, respectively.
Comparison of latency in mammary carcinoma develop-
ment was examined by unpaired Student's t-test.
Results and discussion
Histopathological features of tumours developed in F1 
mice doubly heterozygous for p53 and Atm null alleles
Mammary carcinomas occurred in BALB/c mice of the
p53+/- genotype, and tumours of similar macroscopic mor-
phologies were also observed in the (BALB/c × MSM/
Ms)F1–p53+/-  mice. The histological features of these
tumours in the mammary glands are shown in Fig.
1a,1b,1c,1d,1e,1f, which indicates that they are adenocar-
cinomas. The histopathology of the tumours in nonirradi-
ated mice (Fig. 1a,1b) exhibited more hyperplastic lesions
than did those in irradiated mice (Fig. 1c,1d,1e,1f), but
basically there were no marked differences between the
two groups. There was also no remarkable difference in his-
topathological features between Atm+/- (Fig. 1c,1d) and
Atm+/+ mice (Fig. 1e,1f) in the irradiated groups. These
tumours formed glands lined by highly pleomorphic cells
exhibiting frequent mitosis, and were classified as glandular
adenocarcinomas, high grade according to the Annapolis
Pathology Classification [26].
Lymphomas (Fig. 1g), mainly thymic lymphomas, were effi-
ciently induced by exposure to X-rays, regardless of p53
and Atm genotype, although only a few lymphomas were
observed in nonirradiated mice. Ovarian carcinomas, oste-
osarcomas (Fig. 1h) and hepatomas developed spontane-
ously. Squamous cell carcinomas, basal cell carcinomas,
histiocytic sarcomas and granulocytic leukaemias were
also observed in irradiated mice.
Spontaneous tumour development in mice with four 
genotypes for p53 and Atm
Twenty-eight p53+/- Atm+/-, 22 p53+/- Atm+/+, 11 p53+/+
Atm+/- and 25 p53+/+ Atm+/+ mice were examined for spon-
taneous development of tumours until age 26 months (113
weeks). Fourteen out of 28 p53+/- Atm+/- mice (50%) and
seven out of 22 p53+/- Atm+/+ mice (32%) developed mam-
mary carcinomas during the period of observation (Table 1,
Fig. 2). The incidence of mammary carcinomas in p53+/-
Atm+/- mice appeared to be higher than that in p53+/- Atm+/
+  mice, but the incidences did not differ significantly
between  Atm+/-  and  Atm+/+  genotypes (P  = 0.32, by
Fisher's exact probability test). Among the tumours that
developed in the p53+/- mice, mammary carcinoma were
the most common. These mammary carcinomas were
mainly observed at 41–77 weeks after birth (Fig. 2). No sig-
nificant difference in latency in the nonirradiated groups
was observed between doubly heterozygous mice and p53
singly heterozygous mice (P = 0.47, by unpaired Student's
t-test). None of 11 p53+/+ Atm+/- mice and 25 p53+/+ Atm+/
+ mice developed mammary carcinomas. Several lympho-
mas and a few other tumours developed in the four geno-
types (Table 1). Thus, mammary carcinoma development
depended strongly on p53  heterozygous deficiency in
(BALB/c × MSM/Ms)F1 mice, and p53+/- mice of both
Atm+/+  and  Atm+/-  genotypes developed mammary
carcinoma.
Figure 1
Histopathology of tumours in (BALB/cHeA × MSM/Ms)F1 mice with  genotypes p53+/- Atm+/-, p53+/- Atm+/+ or p53+/+ Atm+/- Histopathology of tumours in (BALB/cHeA × MSM/Ms)F1 mice with 
genotypes p53+/- Atm+/-, p53+/- Atm+/+ or p53+/+ Atm+/-. (a, b) Sponta-
neously developing mammary adenocarcinoma from p53+/- Atm+/- 
mouse. (c, d) Mammary adenocarcinoma from X-irradiated p53+/- Atm+/
- mouse. (e, f) Mammary adenocarcinoma from X-irradiated p53+/- Atm+/
+ mouse. (g) Osteosarcoma observed in nonirradiated p53+/- Atm+/- 
mouse. (h) Thymic lymphoma from p53+/+ Atm+/- mouse exposed to X-
rays. Panels a, c and e: 40×. Panels b, d, f, g and h: 100×.Breast Cancer Research    Vol 7 No 1    Umesako et al.
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Enhancement of mammary carcinogenesis in Atm 
heterozygous deficient mice by X-irradiation
To test the effect of haploinsufficiency of the Atm gene on
mammary carcinogenesis after X-irradiation in p53+/- mice,
55 p53+/- Atm+/-, 61 p53+/- Atm+/+, 47 p53+/+ Atm+/- and
53  p53+/+ Atm+/+ mice (for a total of 216 mice) were
exposed to X-rays (5 Gy) at age 5 weeks. Only one out of
53 p53+/+ Atm+/+ mice and none of 47 p53+/+ Atm+/- mice
developed mammary carcinoma, indicating that almost all
p53+/+ mice fail to develop mammary carcinomas, despite
X-irradiation and irrespective of Atm gene status. In con-
trast, 32 out of 55 p53+/- Atm+/- mice (58%) and 19 out of
61 p53+/- Atm+/+ mice (31%) developed mammary carcino-
mas (Table 2, Fig. 2). The proportion of mice developing
mammary carcinomas in the p53+/- Atm+/- group was signif-
icantly greater than that in the p53+/- Atm+/+ group (P =
0.0034, by χ2 test). A total of 52 mammary carcinomas
developed in 55 p53+/- Atm+/- mice (average number of
mammary carcinomas/mouse = 0.95), whereas 28 mam-
mary carcinoma developed in 61 p53+/- Atm+/+ mice (aver-
age number of mammary carcinomas/mouse = 0.46; Table
2). The average number of mammary carcinomas per
mouse in the p53+/- Atm+/- group was significantly greater
than that in p53+/- Atm+/+ mice (P = 0.0052, by Mann–
Whitney U-test). Thus, Atm  heterozygous deficiency
enhanced development of mammary carcinoma in irradi-
ated p53 heterozygous knockout mice. Spring and cowork-
ers [14] observed no tumours in Atm knockout (Atm+/-)
heterozygous mice. Mice bearing a knockout allele of Atm
and humans carrying a mutant allele of truncated type in the
ATM gene have been shown not to have obviously elevated
susceptibility to mammary carcinogenesis. Our findings
show that heterozygosity for a null knockout allele of Atm
enhances mammary carcinogenesis under p53+/- status,
although the Atm mutation is not a dominant-negative type.
Heterozygous deficiency of p53  might make clear the
effect on mammary carcinogenesis of haploinsufficiency in
the Atm gene.
These mammary carcinomas were observed significantly
earlier (at 18–38 weeks after irradiation; i.e. 23–43 weeks
of age) than in the nonirradiated group (age 41–75 weeks;
Fig. 2). In particular, mammary carcinomas frequently devel-
oped 23–28 weeks after irradiation. The mean (± standard
deviation) latency periods were 32.6 ± 4.8 and 29.8 ± 3.6
weeks in p53+/- Atm+/- and p53+/- Atm+/+ mice, respectively.
Thus, X-irradiation at 5 Gy at age 5 weeks considerably
shortened the latency period of mammary carcinoma
development in these two groups with different genotypes.
As shown in Tables 1 and 2, the incidences of mammary
carcinoma in p53+/- Atm+/- mice were 58% (32 out of 55)
and 50% (14 out of 28) in irradiated and nonirradiated
groups, respectively; in p53+/- Atm+/+ mice the incidence in
the irradiated group was 31% (19 out of 61) and that in the
nonirradiated group was 32% (7 out of 22). The incidence
of mammary carcinoma for each genotype was similar
Table 1
Incidence of tumours developing spontaneously in (BALB/cHeA × MSM/Ms)F1 female mice that were heterozygously deficient for 
p53 and/or Atm genes
Genotypes p53+/- p53+/+
Atm+/- (n = 28) Atm+/+ (n = 22) Atm+/- (n = 11) Atm+/+ (n = 25)
Mammary carcinoma 14 (50%)a 7 (32%) 0 (0%) 0 (0%)
Lymphoma 3 (11%) 3 (14%) 2 (18%) 4 (16%)
Ovarian carcinoma 1 (4%) 1 (5%) 0 (0%) 1 (4%)
Osteosarcoma 1 (4%) 0(0%) 0 (0%) 0 (0%)
Hepatoma 1 (4%) 0(0%) 0 (0%) 0 (0%)
Number of mammary carcinomas/mouseb 14/28 (0.50) 7/22 (0.32) 0/11 (0.00) 0/25 (0.00)
aNumber of mice with tumours. bTotal number of mammary carconomas developing in mice with given genotypes/number of mice examined; 
numbers in parentheses are average numbers of tumours per mouse.
Figure 2
Cumulative incidence of mammary carcinomas in irradiated and nonirra- diated (BALB/cHeA × MSM/Ms)F1 mice with p53+/- Atm+/- or p53+/-  Atm+/+ genotype Cumulative incidence of mammary carcinomas in irradiated and nonirra-
diated (BALB/cHeA × MSM/Ms)F1 mice with p53+/- Atm+/- or p53+/- 
Atm+/+ genotype.Available online http://breast-cancer-research.com/content/7/1/R164
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between irradiated and non-irradiated groups. Thus, irradi-
ation may not elevate the incidence of the tumours.
Altogether, irradiation markedly hastened mammary carci-
noma development in the p53+/- mice, in which mammary
carcinomas developed spontaneously. Furthermore, irradi-
ation also induced lymphomas, mainly thymic lymphomas,
in all four genotypes of mice. The incidence of the lympho-
mas did not differ significantly among the four groups, with
different genotypes for p53 and Atm genes. A high inci-
dence of thymic lymphoma was observed in previous stud-
ies performed using p53 heterozygous deficient F1 mice
[17,28]. In the present study an extremely high incidence of
tumours, most of which were mammary carcinomas and
thymic lymphomas, was observed in irradiated p53+/- Atm+/
- mice.
Status of wild-type alleles of p53 and Atm in mammary 
carcinoma
The wild-type alleles of the p53 and Atm genes were exam-
ined in mammary carcinoma tissue from heterozygous
mice. The wild-type p53 allele was lost in 25 (96%) out of
26 mammary carcinomas from irradiated p53+/- mice and in
all of 15 mammary carcinomas from nonirradiated p53+/-
mice, regardless of Atm gene status. Only one mammary
carcinoma in irradiated p53+/+ Atm+/+ mice (Table 2) was
found to retain the p53 wild-type allele. On the other hand,
wild-type Atm allele was preserved in all of 17 mammary
carcinomas from irradiated Atm+/- mice and in all of 10
mammary carcinomas from irradiated Atm+/+ mice, regard-
less of p53 gene status. Wild-type Atm allele was also
retained in nine out of 10 mammary carcinomas from nonir-
radiated Atm+/- mice and in all of five mammary carcinomas
from nonirradiated Atm+/+ mice. These results suggest that
the homozygous loss of the p53 allele was a necessary
condition for the development of mammary carcinomas,
whereas the Atm null allele exhibited haploinsufficiency.
Haploinsufficiency for tumour development was reported
for the Nbn  knockout mice, the mouse homologue of
NBS1. Heterozygosity for the Nbn  knockout allele ren-
dered the mice susceptible to tumour development, yet the
Nbn wild-type allele was fully retained in all 12 tumours
examined [29]. p27 heterozygotes are also predisposed to
tumours in multiple tissues when challenged with irradia-
tion or a chemical carcinogen, and in the developed
tumours the remaining wild-type allele is neither mutated
nor silenced, indicating that p27  is haploinsufficient for
tumour suppression [30]. In that study, heterozygous Atm
knockout enhanced mammary carcinoma development in
p53-heterozygous deficient mice, but the effect of Atm defi-
ciency was not as profound. A previous study showed that
heterozygosity for the Atm knockout allele did not enhance
tumour development but that dominant-negative type mis-
sense mutations in the Atm gene did [14]. In humans, het-
erozygosity of the truncation-type mutations, which
represent the majority of Atm  mutations that occur in
humans, had no effect on carcinogenesis, suggesting that
enhancement in tumourigenesis depends strongly on muta-
tion type. However, in the present study we demonstrated
Table 2
Incidence of tumours in irradiated (BALB/cHeA × MSM/Ms) F1 female mice that were heterozygously deficient for p53 and/or Atm 
genes
Genotypes p53+/- p53+/+
Atm+/- (n = 55) Atm+/+ (n = 61) Atm+/- (n = 47) Atm+/+ (n = 53)
Mammary carcinoma 32 (58%)a* 19 (31%) 0 (0%) 1 (2%)
Lymphoma 24 (44%)b 29 (48%) 26 (55%) 22 (42%)
Squamous cell carcinoma 1 (2%) 1 (2%) 0 (0%) 0 (0%)
Histiocytic sarcoma 1 (2%)c 0 (0%) 0 (0%) 0 (0%)
Basal cell carcinoma 0 (0%) 1 (2%) 0 (0%) 0 (0%)
Granulocytic leukaemia 0 (0%) 1 (2%) 0 (0%) 0 (0%)
Ovarian carcinoma 0 (0%) 1 (2%) 0 (0%) 0 (0%)
Nonthymic lymphoma (NOS) 0 (0%) 1 (2%) 3 (6%) 0 (0%)
Solid tumour (NOS) 1 (2%)d 1 (2%)e 1 (2%) 1 (2%)
Number of mammary carcinomas/mousee 52/55 (0.95)** 28/61 (0.46) 0/47 (0.00) 1/53 (0.02)
aNumber of mice with tumours; percentage in parenthesis is the proportion of mice developing mammary carcinoma. bThree animals developed 
both lymphomas and mammary carcinoma. cOne animal developed both histiocytic sarcoma and mammary carcinoma. dTumour in abdomen. 
eTotal number of mammary carcinomas developing in mice with given genotypes/number of mice examined; numbers in parentheses are average 
numbers of tumours per mouse. *The proportion of mice developing tumours is significantly greater than that in p53+/- Atm+/+ mice (P = 0.0034 by 
c2 test). **The average number of tumours/mouse is significantly greater than that in p53+/- Atm+/+ mice (P = 0.0052 by Mann–Whitney U-test). 
NOS, not otherwise specified.Breast Cancer Research    Vol 7 No 1    Umesako et al.
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that haploinsufficiency does occur for the Atm null allele in
combination with heterozygous deficiency in the p53 gene.
The  p53  heterozygous deficient BALB/c mice, which
developed mammary carcinomas early and efficiently, may
represent a useful model for the study of effects of genes
other than Atm  on mammary carcinogenesis. F1  mice
between different subspecies may also provide an experi-
mental system for precise genome-wide allelotype analysis
of genes that cooperate with p53.
Conclusion
Tumourigenesis is strongly enhanced in mice with homoge-
neous deficiency in the p53 or Atm gene. In the present
study we tested the effect of haploinsufficiency of the Atm
gene on mammary tumourigenesis after X-irradiation in
p53+/- mice of the BALB/cHeA × MSM/Ms background.
Singly heterozygous p53+/- mice X-irradiated (5 Gy) at age
5 weeks developed mammary carcinomas at around 25
weeks of age, and the final incidence of mammary carci-
noma at 39 weeks was 31% (19 out of 61). Introduction of
the heterozygous Atm alleles into the background of the
p53+/- genotype significantly increased the incidence of
mammary carcinomas to 58% (32 out of 55) and increased
the average number of mammary carcinomas per mouse.
However, it apparently did not change the latency of mam-
mary carcinoma development. In nonirradiated mice, intro-
duction of the Atm+/- allele into p53+/- mice also tended to
increase spontaneous incidence of mammary carcinoma. In
contrast, almost none of the p53+/+ mice developed mam-
mary carcinoma, regardless of the Atm gene status and
whether mice were subjected to irradiation. In almost all of
the spontaneous and radiation-induced mammary carcino-
mas, the wild-type p53 allele was found to be lost whereas
the wild-type Atm allele was retained, suggesting haploin-
sufficiency of the latter gene in mammary carcinoma devel-
opment. Thus, doubly heterozygous mice represent a
useful model system with which to analyze the interaction
of heterozygous genotypes for p53, Atm and other genes
and their effect on mammary carcinogenesis.
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